Search Results - "amyloid"

Abeta toxicity Part 1 /

Table of Contents: “…Contents: The amyloid plaque -- Impact of delaying onset of AD -- The amyloidocentric theory of Alzheimer's disease -- Compelling evidence for the Abeta theory of AD -- Delay onset of AD by 5 years -- The best target for a disease-modifying drug -- APP structure and domains -- Iron-export ferroxidase activity of beta-amyloid precursor protein -- Age at onset correlates with Abeta isoforms -- Activation of PS1 -- Abeta amyloid -- The mechanism of neurodegeneration -- Abeta metal binding modes -- Current working model of Abeta toxicity -- Abeta amyloid protein: current model consistent with EXAFS -- Metal-protein attenuating compound (MPAC) with moderate affinity for metals -- Clioquinol (CQ, PBT1) the prototypic MPAC -- PBT2: SAR based on rational drug design -- CQ (PBT1) vs. …”
Get full text
Series (Alzheimer disease)
Series (Drug discovery and development in the neurosciences)

Abeta toxicity 1

Table of Contents: “…Contents: The amyloid plaque -- Impact of delaying onset of AD -- The amyloidocentric theory of Alzheimer's disease -- Compelling evidence for the Abeta theory of AD -- Delay onset of AD by 5 years -- The best target for a disease-modifying drug -- APP structure and domains -- Iron-export ferroxidase activity of beta-amyloid precursor protein -- Age at onset correlates with Abeta isoforms -- Activation of PS1 -- Abeta amyloid -- The mechanism of neurodegeneration -- Abeta metal binding modes -- Current working model of Abeta toxicity -- Abeta amyloid protein: current model consistent with EXAFS -- Metal-protein attenuating compound (MPAC) with moderate affinity for metals -- Clioquinol (CQ, PBT1) the prototypic MPAC -- PBT2: SAR based on rational drug design -- CQ (PBT1) vs. …”
Get full text
Series (Alzheimer disease)
Series (Drug discovery and development in the neurosciences)

Abeta toxicity 1

Table of Contents: “…Contents: The amyloid plaque -- Impact of delaying onset of AD -- The amyloidocentric theory of Alzheimer's disease -- Compelling evidence for the Abeta theory of AD -- Delay onset of AD by 5 years -- The best target for a disease-modifying drug -- APP structure and domains -- Iron-export ferroxidase activity of beta-amyloid precursor protein -- Age at onset correlates with Abeta isoforms -- Activation of PS1 -- Abeta amyloid -- The mechanism of neurodegeneration -- Abeta metal binding modes -- Current working model of Abeta toxicity -- Abeta amyloid protein: current model consistent with EXAFS -- Metal-protein attenuating compound (MPAC) with moderate affinity for metals -- Clioquinol (CQ, PBT1) the prototypic MPAC -- PBT2: SAR based on rational drug design -- CQ (PBT1) vs. …”
Get full text
Series (Alzheimer disease)
Series (Drug discovery and development in the neurosciences)

Frontotemporal dementia

Table of Contents: “…Contents: Prevalence and nomenclature of FTD -- The pathology of FTD (tau, TDP-43) -- The genetics of FTD (tau, progranulin) -- Patterns of atrophy and neuroanatomical correlates of behavior and cognition -- von Economo neurons -- Neuroimaging (amyloid imaging) -- Treatment.…”
Get full text
Series

Frontotemporal dementia

Table of Contents: “…Contents: Prevalence and nomenclature of FTD -- The pathology of FTD (tau, TDP-43) -- The genetics of FTD (tau, progranulin) -- Patterns of atrophy and neuroanatomical correlates of behavior and cognition -- von Economo neurons -- Neuroimaging (amyloid imaging) -- Treatment.…”
Get full text
Series

Immunotherapy as an approach to treating Alzheimer's disease

Table of Contents: “…Contents: Alzheimer's Disease -- Immunization with amyloid-beta (A-beta) -- Radial arm water maze -- Clinical trial of anti-A-beta vaccine -- Mechanisms of antibody-mediated A-beta clearance -- Catalytic fibril dissolution -- Peripheral sink hypothesis -- Systemic administration of anti-A-beta antibodies into old APP transgenic (Tg) mice -- Diffuse and compact amyloid deposits -- Systemic anti-A-beta antibody -- Parenchymal and vascular amyloid deposits -- Microhemorrhages -- A possible solution to the problems of immunotherapy -- Systemic administration experimental design -- Intact and deglycosylated antibodies reverse cognitive decline -- Current clinical trials of A-beta immunotherapy -- Prospects for immunotherapy.…”
Get full text
Series

Immunotherapy as an approach to treating Alzheimer's disease

Table of Contents: “…Contents: Alzheimer's Disease -- Immunization with amyloid-beta (A-beta) -- Radial arm water maze -- Clinical trial of anti-A-beta vaccine -- Mechanisms of antibody-mediated A-beta clearance -- Catalytic fibril dissolution -- Peripheral sink hypothesis -- Systemic administration of anti-A-beta antibodies into old APP transgenic (Tg) mice -- Diffuse and compact amyloid deposits -- Systemic anti-A-beta antibody -- Parenchymal and vascular amyloid deposits -- Microhemorrhages -- A possible solution to the problems of immunotherapy -- Systemic administration experimental design -- Intact and deglycosylated antibodies reverse cognitive decline -- Current clinical trials of A-beta immunotherapy -- Prospects for immunotherapy.…”
Get full text
Series

Immunotherapy as an approach to treating Alzheimer's disease

Table of Contents: “…Contents: Alzheimer's Disease -- Immunization with amyloid-beta (A-beta) -- Radial arm water maze -- Clinical trial of anti-A-beta vaccine -- Mechanisms of antibody-mediated A-beta clearance -- Catalytic fibril dissolution -- Peripheral sink hypothesis -- Systemic administration of anti-A-beta antibodies into old APP transgenic (Tg) mice -- Diffuse and compact amyloid deposits -- Systemic anti-A-beta antibody -- Parenchymal and vascular amyloid deposits -- Microhemorrhages -- A possible solution to the problems of immunotherapy -- Systemic administration experimental design -- Intact and deglycosylated antibodies reverse cognitive decline -- Current clinical trials of A-beta immunotherapy -- Prospects for immunotherapy.…”
Get full text
Series

Alzheimer's disease where are we up to? /

Table of Contents: “…Contents: Advances in technology -- Alzheimer: senile plaques -- Examples of risk loci for Alzheimer's disease (AD) -- TREM2 mutations in AD -- Genomic analysis of Alzheimer's disease -- Plaque and amyloid pathology -- Lipid metabolism in the aetiology of AD -- Risk factors expressed in the innate immune system -- Implications for therapy.…”
Get full text
Series (Periodic reports)
Series (Alzheimer's disease)

Alzheimer's disease where are we up to? /

Table of Contents: “…Contents: Advances in technology -- Alzheimer: senile plaques -- Examples of risk loci for Alzheimer's disease (AD) -- TREM2 mutations in AD -- Genomic analysis of Alzheimer's disease -- Plaque and amyloid pathology -- Lipid metabolism in the aetiology of AD -- Risk factors expressed in the innate immune system -- Implications for therapy.…”
Get full text
Series (Periodic reports)
Series (Alzheimer's disease)

Alzheimer's disease where are we up to? /

Table of Contents: “…Contents: Advances in technology -- Alzheimer: senile plaques -- Examples of risk loci for Alzheimer's disease (AD) -- TREM2 mutations in AD -- Genomic analysis of Alzheimer's disease -- Plaque and amyloid pathology -- Lipid metabolism in the aetiology of AD -- Risk factors expressed in the innate immune system -- Implications for therapy.…”
Get full text
Series (Periodic reports)
Series (Alzheimer's disease)